Therefore, targeting cardiac lymphangiogenesis using LEPC transplantation and VEGF-C release from SAP is a feasible strategy for therapeutic intervention of cardiac edema in cardiovascular diseases. The gene discussed is VEGFC; the disease is cardiovascular disorder.